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Gisela Tunes da Silva,1 Brent R. Logan,2 John P. Klein3Classical hypothesis testing focuses on testing whether treatments have differential effects on outcome.
However, sometimes clinicians may be more interested in determining whether treatments are equivalent
or whether one has noninferior outcomes. We review the hypotheses for these noninferiority and equiva-
lence research questions, consider power and sample size issues, and discuss how to perform such a test for
both binary and survival outcomes. The methods are illustrated on 2 recent studies in hematopoietic cell
transplantation.
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Most studies of factors affecting outcome in hema-
topoietic stem cell transplantation (HSCT) are based
on a classical hypothesis testing formulation. In this
formulation the investigator poses the question ‘‘do
these factors have differential effects on outcome’’?
The tests are designed to protect the null hypothesis
that the factors have no influence on survival or what-
ever outcome is of primary interest. The tests are de-
signed to make decisions about a difference in
outcome which is indicated by a small P-value.
When the P-value is large in many cases investigators
conclude incorrectly that the factor has no effect on
outcomes. No evidence of a difference in such studies
may be a result of inadequate sample sizes, small treat-
ment differences or simply chance.
As an example of this problem, consider the recent
study of the effects of HLA matching on unrelated do-
nor transplants [1]. Here, classical hypothesis testing
asks questions like ‘‘does a patient with a 7/8 donor
transplant have different survival then one with an
8/8 donor?’’ or ‘‘Is the survival different for a patient1Department of Statistics, University of Sao Paulo, Sao
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6/j.bbmt.2008.10.004if they had a 7/8 A mismatched donor than if they
had a 7/8 B mismatched donor?’’ What may be of
more clinical interest is whether a 7/8 donor can be
substituted for an 8/8 donor, so that the primary ques-
tion is either ‘‘Do patients with a 7/8 and 8/8 donor
have equivalent survival’’ or ‘‘Do patients with 7/8 do-
nors have survival which is not inferior to an 8/8
donor.’’ We could ask similar questions about the
choice of which loci a 7/8 donor was mismatched at.
Another example is a study to compare peripheral
blood stem cells (PBSC) versus bone marrow (BM)
as a cell source for unrelated donor transplants for pa-
tients with leukemia undergoing myeloablative trans-
plants [2]. The advantage of peripheral blood over
BM is that the collection is easier for the donor, be-
cause no anesthesia, hospitalization, and potential ex-
posure to blood products is needed. Studies in
related donors have indicated faster engraftment for
PBSC, along with potentially greater graft-versus-
host disease (GVHD) burden and lower relapse risk.
Given the GVHD burden of PBSC, clinicians may
be interested in learning whether BM is not inferior
to PBSC in terms of survival.
Clinical trials are often conducted with new exper-
imental treatments or therapies that may reduce side
effects, costs, or have another advantage over the usual
standard treatment. In these situations, the new treat-
ment is often compared to the standard with the aim of
showing it is therapeutically equivalent or not inferior.
A new treatment is called equivalent if its outcome
does not differ from that of the standard therapy by
more than a prespecified clinically significant amount,
although it is called noninferior if its outcome is no
worse than that of the standard by a prespecified
amount. These types of studies require that we refor-
mulate hypotheses and that we look at testing in a
different light.
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a Binary Endpoint
For simplicity, we will discuss tests that have a sin-
gle binary outcome (success or failure). This outcome
could be engraftment, GVHD, or death at some time.
If we are interested in a specific time (eg, survival at
1 year or engraftment at 100 days), the outcome for
each patient is his/her status (dead/alive or engraft-
ment/no engraftment), so that we have a binary end-
point. We assume that there is no censoring, so that
the status for each patient is known at the time of inter-
est. Formulation of the hypotheses depends on
whether we focus on the probability of a good outcome
(survival, engraftment) or the probability of a bad out-
come (GVHD, death). First we focus on the former,
where pT and pC are probabilities of a good outcome
(eg, survival, engraftment) in the treatment group
and control group, respectively.
The hypotheses for noninferiority and equivalence
can be stated in terms of a number of different mea-
sures of relative efficacy. The most commonly used
ones are the difference in proportions D 5 pT – pC or
the odds ratio
OR5
pT
1--pT
 1--pC
pC
:
We shall first consider the difference of propor-
tions D. Recall that the classical hypothesis testing
framework tests the null and alternative hypotheses
H0 : D5pT--pC50
HA : D5pT--pCs0: (1)
The null hypothesis says that there is no differ-
ence between the treatment and the control, and we
are trying to show that there really is a difference
(the alternative hypothesis). Here we control the prob-
ability of a type I error (often at 5%), which is the
chance that we incorrectly reject the null hypothesis,
or conclude that there is a difference when, in fact,
there really is no difference in outcomes. This control
of the type I error rate protects us against incorrectly
identifying a difference between the 2 treatments
when they are the same. However, note that when we
are testing the hypothesis given by (1) and if we fail
to reject the null hypothesis, we cannot conclude that
the treatments are equivalent, we only can say that
there is not enough evidence to show a difference be-
tween the treatments. Formal establishment of nonin-
feriority or equivalence requires testing of a different
set of hypotheses as well as prespecification of an
equivalency threshold as described below.
The hypotheses for noninferiority are reversed
somewhat from this classical formulation. The hy-
potheses for noninferiority in this situation areH0 : D5pT--pC#--d
HA : D5pT--pC.--d; (2)
where d . 0 is the noninferiority margin of clinical
interest. Here, the null hypothesis is stating that the
treatment success rate is at least an amount d worse
than the control success rate, whereas the alternative
hypothesis that we want to prove is stating that the
treatment is noninferior. Noninferiority here means
that the treatment rate can be no worse than d lower
than the control rate. For example, if the treatment is
cells from a 7/8 donor and the control is cells from
a 8/8 donor, p the probability of 1-year survival and
d 5 0.1, we would say that the 7/8 donor transplant
was noninferior to an 8/8 donor if the 1-year survival
probability is no more than 10% lower with the 7/8
donor than with an 8/8 donor.
The type I error rate for these tests is now the like-
lihood that we conclude the treatment group is not in-
ferior to the control, when in fact it really is inferior.
When we control the type I error for these noninfer-
iority hypotheses, we are protecting against incorrectly
concluding noninferiority for the treatment group
compared to the control group.
Note that these noninferiority hypotheses require
that one define a noninferiority margin. This noninfer-
iority margin should be based on clinical judgment and
it has the interpretation of how close the new treat-
ment must be to the control to be considered equiva-
lent (or noninferior). The choice of the margin d is
a critical issue and a difficult task [3-5]. As pointed
out by Rousson et al. [5], when the hypotheses are
stated in terms of the difference D, the value of
d may depend on the value of the control group prob-
ability of success pC. The margin d should be smaller
than pC because it makes no sense to test if pT is greater
or smaller than a negative number. This may be viewed
as a disadvantage over stating the hypotheses in terms
of the odds ratio. We explore the relationship between
the noninferiority margin and the scale of the treat-
ment effect in a later section.
The noninferiority hypotheses above apply when
we define the probabilities pT and pC as probabilities
of a good outcome. However, if pT and pC refer to prob-
abilities of a bad outcome (GVHD or death), then the
directions of the inequalities need to be switched
around. This reflects the fact that noninferiority now
means that the treatment outcome probability is not
much higher than the control outcome. The correct
specification of the noninferiority hypothesis would be
H0 : D
5pT--p

c$d

HA : D
5pT--p

c\d
:
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appropriate than a noninferiority test. For such tests
we want to show that the treatment and control out-
comes are within a specified amount of one another
in either direction. The equivalence hypotheses are
H0 : D5
pT--pC$d
HA : D5
pT--pC\d; (3)
where d. 0 is the margin of clinically accepted differ-
ence. Here, the null hypothesis states that the treat-
ment success proportion is different from the control
proportion by at least an amount d, whereas the
alternative hypothesis states that it is equivalent
(within d of the control proportion). The type I error
rate is the likelihood that we conclude the treatments
are equivalent when in fact they are not.
Noninferiority and Equivalence Tests and
Confidence Intervals for a Binary Endpoint
Assume initially that we are interested in testing
the noninferiority hypothesis (2). Following Laster
et al. [6], the test statistic used for this test is very sim-
ilar to the usual test for proportions; the only differ-
ence is that we need to add the non inferiority
margin d in the numerator. The test statistic for testing
(2) is then given by
z5
bpT--bpC1dﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃbpT1--bpT
nT
1
bpC1--bpC
nC
s ; (4)
where bpT and bpC are the observed proportions of suc-
cess in the treatment and control groups, respectively,
nT and nC are the sample sizes of the corresponding
groups. For large enough sample sizes, this test statis-
tic has a standard normal distribution under the null
hypothesis. Thus, noninferiority is concluded at the
level a if z . z1–a, where z1–a is the (1–a)-percentile
of a standard normal distribution. The noninferiority
P-value is given by PNI 51 – F(z), where F (z) is the
probability that a standard normal random variable is
less than z.
An equivalent way of verifying noninferiority is by
computing a 1-sided confidence interval for the differ-
ence in proportions and rejecting the null hypothesis if
–d is below the confidence bound. More precisely, fol-
lowing Phillips [7], the 1-sided lower confidence
bound for the difference is given by
LB5bpT--bpC--z1--a
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃbpT1--bpT
nT
1
bpC1--bpC
nC
s
and the null hypothesis is rejected if LB . –d. Note
that LB is the lower limit of the usual 2-sided intervalwhere we use a confidence coefficient of (1 – 2a) 
100% (ie, we use z1–a) rather than the usual (1 – a) 
100% (ie, z1–a/2) confidence interval. For example, if
we are testing for noninferiority with a 5% significance
level, we would construct a 90% 2-sided confidence in-
terval and use the lower bound to determine noninfer-
iority.
Two-sided confidence intervals are usually useful
in equivalence testing, where one is interested in the
composite hypothesis (3). The equivalence hypothesis
is often tested by comparing the (1 – 2a)100%
confidence limits of the difference in proportions
with the limits (–d;d) and the null hypothesis is rejected
(ie, equivalence is claimed) if the entire interval falls
within (–d;d).
This confidence interval approach is operationally
the same as conducting 2 tests with hypothesis given by
H0L : D5pT--pC#--d
HAL : D5pT--pC.--d (5a)
and
H0U : D5pT--pC$d
HAU : D5pT--pC\d: (5b)
The test statistic for (5a) is the same as that given
in (2); however, the test statistic for (5b) is:
z5
bpT--bpC--dﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃbpT1--bpT
nT
1
bpC1--bpC
nC
s (6)
and we reject that null hypothesis if z\ za. In order
to be equivalent to the confidence interval method,
the critical region for both 1-sided tests must be
constructed based on a significance level equal to
a (Lewis [8]).Power and Sample Size Considerations for
Binary Outcomes
Power has a different interpretation when we are
doing noninferiority testing than when we are per-
forming a traditional hypothesis test. In the classical
hypothesis testing framework, power refers to the like-
lihood that we correctly conclude the treatments are
different. In the noninferiority setting, power refers
to the likelihood that we correctly conclude the treat-
ment is noninferior, when it really is noninferior.
Power depends both on the noninferiority margin
d and the true difference in proportions e, between
the treatment and control arms. To evaluate power
when the treatment is considered noninferior, we usu-
ally assume that the treatment and standard have the
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nT5 nc5 n, the sample size required to have a prespe-
cified power 1 – b is given by
n5
2ðz1--a1z1--bÞ2pC

1--pC

d2
where zb is the value such that F(z1–b) 51 – b. For
the common values of a 5 0.05 and b 5 0.2, this
reduces to
n5
12:35pC

1--pC

d2
:
Note that this formula looks similar to the sam-
ple size formula for the usual testing problem, except
that the true difference, e used in the usual formula-
tion, is replaced by the noninferiority margin d. This
is an important difference. Often researchers plan
a study to detect a 20% difference in success rates
with 80% power, for example, so that e 5 0.2. How-
ever, a margin for considering a treatment noninferior
might be much smaller, say d5 5% or 10%. This nar-
rower margin results in the generally larger sample
sizes often associated with noninferiority testing.
For equivalence testing, the formula for comput-
ing the sample size is similar, but an adjustment must
be made because we are actually performing two
1-sided tests (see Farrington [9]):
neq5
2

z1--a1z1--b=2
2
pC

1--pC

d2
:
Notice that the adjustment is made on the nor-
mal percentile corresponding to the power: we use
now z1–b/2 instead of z1–b.
Table 1 illustrates examples of sample sizes per
treatment arm required to determine noninferiority
and equivalence for a variety of settings, using pC 5
0.5. (Note that pC is a worst case scenario because pC
(1 – pC) has its largest values when pC 5 0.5). In Table
2 we show the minimum d that should be used in order
to have an 80% or 90% power to detect noninferiorityTable 1. Sample Sizes per Treatment Arm for Different
Powers and a 5 5%
Power d Sample Size Noninferiority Sample Size Equivalence
80% 0.010 30,876 42,778
0.025 4940 6844
0.050 1235 1711
0.075 549 761
0.100 309 428
0.150 137 190
90% 0.010 42,778 54,120
0.025 6844 8659
0.050 1711 2165
0.075 761 962
0.100 428 541
0.150 190 241for 2 different values of pC (0.5 and 0.9). Note that the
value of d is smaller when pC is farther from 1/2. It is
also interesting to see that to use the very liberal
610% cutoff for equivalence we need over 856 pa-
tients (428 per arm) to have just an 80% chance of
showing equivalence. The usual test of the hypothesis
(1), on the other hand needs only a sample size of 776
(388), a savings of 80 patients to have 80% power to
detect a 10% difference in probability when pC 5 1/2
and pT 5 0.6.
Noninferiority and Equivalence Hypotheses in
Terms of Odds Ratio
The hypothesis may be stated in terms of the odds
ratio instead of the difference D. The use of the odds
ratio has some advantages over the difference D: it
takes values between zero and infinity for any value
of pC, so that the choice of the margin does not depend
on pC; it is symmetric when success and failure are in-
terchanged. The hypotheses for noninferiority in
terms of the odds ratio are given by
H0 : OR#d0R
HA : OR.dOR; (7)
where 0\ dOR\ 1 is the clinically significant odds
ratio margin, and assuming that we are focusing on
the odds of a good outcome such as survival or
engraftment. For equivalence testing we consider the
hypotheses (for dOR\ 1)
H0 : OR#dOR or OR$1=dOR
HA : dOR\OR\ð1=dORÞ: (8)
Several authors have suggested values for dOR.
For example, the suggestion made by Senn [10] is
dOR5 0.55, so that the maximum possible noninferior-
ity difference between the 2 proportions of success is
0.15. Note that a particular noninferiority margin on
the odds ratio scale will have different corresponding
noninferiority margins on the difference in propor-
tions scale, depending on the success proportion in
the control arm. This relationship between the nonin-
feriority margins on different scales is shown in
Figure 1. For each of several noninferiority margins
on the difference scale, d, the corresponding odds ratio
noninferiority margin dOR is plotted against the con-
trol proportion pC. For example, if we considered
10% an appropriate difference noninferiority margin,
the corresponding odds ratio noninferiority margin
would range from approximately 0.45 when pC is 0.2
to approximately 0.65 when pC 5 0.5. Therefore, one
must be very careful in selecting an appropriate nonin-
feriority margin on the odds ratio scale, to ensure that
it is clinically appropriate.
Table 2. Minimum d needed to be Used in Order to Have an 80% or 90% Power, for Different Sample Sizes per Treatment Arm
Sample Size
Noninferiority Equivalence
pC 5 0.5 pC 5 0.9 pC 5 0.5 pC 5 0.9
80% Power 90% Power 80% Power 90% Power 80% Power 90% Power 80% Power 90% Power
50 0.249 0.293 0.149 0.176 0.293 0.329 0.176 0.197
100 0.176 0.207 0.105 0.124 0.207 0.233 0.124 0.140
150 0.144 0.169 0.086 0.101 0.169 0.190 0.101 0.114
200 0.124 0.146 0.075 0.088 0.146 0.164 0.088 0.099
300 0.102 0.119 0.061 0.072 0.119 0.134 0.072 0.081
500 0.079 0.093 0.047 0.056 0.093 0.104 0.056 0.062
800 0.062 0.073 0.037 0.044 0.073 0.082 0.044 0.049
1200 0.051 0.060 0.030 0.036 0.060 0.067 0.036 0.040
1500 0.045 0.053 0.027 0.032 0.053 0.060 0.032 0.036
2000 0.039 0.046 0.024 0.028 0.046 0.052 0.028 0.031
3000 0.032 0.038 0.019 0.023 0.038 0.042 0.023 0.025
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adapted to the odds ratio scale using the confidence in-
tervals approach described previously. First construct
a (1 – 2a) level confidence interval for the odds ratio.
Then if the confidence interval is entirely above dOR
one could conclude noninferiority at the a significance
level. Similarly, if the confidence interval is entirely be-
tween dOR and 1/dOR, one could conclude equivalence
at the a significance level.Noninferiority and Equivalence for Survival
Outcomes
In many situations, it is of interest to show nonin-
feriority or equivalence of treatments in terms of sur-
vival probabilities. Frequently, the assessment of
noninferiority for survival time data is reduced to
a comparison of survival probabilities at a single time
point t. If data is not censored, then methods for bi-
nary outcomes can be applied. However, usually sur-
vival data is right censored and the methods for
testing noninferiority must account for censoring.
For censored data, noninferiority can be tested us-
ing the Kaplan-Meier estimator of the survivor func-Figure 1. Relationship between noninferiority margin on the odds
ratio scale, dOR, and the margin on the difference scale, d.tions of the 2 groups at a single fixed time point t, as
suggested by Com-Nougue [11]. Let ST(t) denote the
survival function of the new treatment group and
SC(t) the survival function of the control group. The
hypotheses for testing noninferiority are exactly as in
(1) with p 5 S(t)
H0 : dðtÞ5STðtÞ--SCðtÞ#--D
HA : dðtÞ5STðtÞ--SCðtÞ.--D: (9)
Confidence intervals for the difference in sur-
vival proportions to test either noninferiority or equiv-
alence are constructed using standard survival analysis
techniques [12] with modified confidence levels as dis-
cussed above for binary endpoints. Test statistics for
noninferiority and equivalence hypotheses are similar
to the ones presented for binary outcomes, only using
the Kaplan-Meier estimator of the survival proportion
and replacing the variance estimator in the denomina-
tor by the Greenwood’s variance estimator of the sur-
vival function. If one is interested in adjusting for
covariates, one can model the odds ratio for survival
at time t using a pseudovalue regression technique
[13-15] with a logit link function, and use the confi-
dence interval techniques described previously for
odds ratios to test noninferiority or equivalence. The
same caveats about the choice of noninferiority thresh-
old on the odds ratio scale hold here as well.
The noninferiority or equivalence hypothesis can
also be stated in terms of the relative risk. This can
be a useful way of testing for noninferiority when ad-
justing for covariates that may be different between
the treatment group and control group. Let hT(t) and
hC(t) be the hazard rates at time t for the groups to
be compared. The relative risk of failure is given by
r(t) 5 hT(t)/hC(t). Testing noninferiority or equiva-
lence using a relative risk threshold is appropriate
when a proportional hazards assumption holds, in
which r(t)5 hT(t)/hC(t)5 r for all t. Then the hypoth-
esis of noninferiority can be stated as
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HA : r\g0; (10)
where g0 . 1 is the acceptable upper limit for
noninferiority. This is an upper bound rather than
a lower bound because higher r corresponds to worse
outcomes. Notice that in this case we are not compar-
ing survival probabilities at 1 time point only, but are
comparing the entire survival curves for evidence of
noninferiority. The Cox proportional hazards [16]
model can be used to estimate and construct confi-
dence intervals for the relative risk. One could
conclude noninferiority if the (1 – 2a) level confidence
interval for the relative risk is entirely below g0. Simi-
larly, one could conclude equivalence if the (1 – 2a)
level confidence interval is entirely between 1/g0
and g0. If one is interested in noninferiority or
equivalence at a single point in time, t, an appropriate
confidence interval for r can be constructed using the
pseudo-observation approach [13] with a complimen-
tary log-log link.
An important issue in noninferiority testing in sur-
vival outcomes is the determination of acceptable
values for noninferiority thresholds D and g0. Al-
though D has a direct clinical interpretation in terms
of the difference in survival probabilities, the hazard
ratio threshold g0 is not so clear. One approach is to
use the relationship between the hazard ratio and the
survival probabilities to determine an appropriate g0.
When the proportional hazards model holds, the
following relation is valid:
STðtÞ5ðSCðtÞÞg or g5logðSTðtÞÞ
logðSCðtÞÞ:
Therefore, for a particular choice of noninfer-
iority threshold g0, the equivalent noninferiority
threshold on the survival probability scale dependsFigure 2. Relationship between noninferiority margin on the relative
risk scale, g0, and the margin on the survival difference scale, D.on the survival probability for the control group. Fig-
ure 2 shows the relative risk noninferiority margins g0
for select survival difference noninferiority margins D,
plotted as a function of SC(t). For example, if we con-
sidered 10% an appropriate survival difference nonin-
feriority margin, the corresponding relative risk
noninferiority margin would range from approxi-
mately 1.3 when SC(t) 5 0.4 to approximately 1.6
when SC(t) 5 0.8. Therefore, one must be especially
careful when picking noninferiority thresholds on the
relative risk scale to be aware of how those noninferior-
ity thresholds translate to the survival probability
scale. These calculations assume that ST and SC do
not depend on other covariates. If these are denoted
by Z and they are modeled in the Cox model or
pseudo-observation regression model assuming
proportional hazards effects then the difference in
survival functions at time t is
D5SoðtÞexp{bZ}2
h
SoðtÞexp{bZ}
ig
:
EXAMPLES
Example 1: PBSC versus BM for Unrelated
Donor Allogeneic Transplants
In this example, we examine whether BM is nonin-
ferior to PBSC in myeloablative unrelated donor
transplantation, using the data from Eapen et al. [2].
If this is the case, the greater GVHD burden of
PBSC might make clinicians less likely to use PBSC
in this setting. We use a noninferiority margin of
10%, and examine treatment-related mortality
(TRM), relapse, leukemia-free survival (LFS), and
overall survival (OS). We first select a time point of
6 months to illustrate the procedures in a binary out-
come framework, because there is no censoring prior
to 6 months. We also show results for 3 years using
the Kaplan-Meier probabilities. The number of pa-
tients experiencing each outcome by 6 months are
shown in Table 3. The Z test statistics for LFS and
OS are from equation (4); the statistics for TRM and
Relapse are from equation (6). Note that the P-values
for TRM, relapse, and LFS are all significant at the
5% level, indicating that BM is not inferior to PBSC
on these outcomes at the 5% significance level. For
OS, the P-value is 0.052, so we cannot conclude non-
inferiority. The 90% confidence intervals for TRM
and relapse are both below 10%, indicating that these
incidences for patients receiving BM are\10% higher
than for patients receiving PBSC. The 90% confidence
interval for LFS is above –10%, indicating that the
LFS for patients receiving BM is no more than 10%
worse than the LFS for patients receiving PBSC. Anal-
ysis of longer term outcomes, such as LFS at 3 years,
would require use of the Kaplan-Meier estimates.
Table 3. Results of Noninferiority Analysis for PBSC versus BM Study at 6 Months
Number of Patients Having Each Outcome at 6 Months
n TRM Relapse LFS OS
BM 583 187 (32%) 93 (16%) 303 (52%) 331 (57%)
PB 328 95 (29%) 58 (18%) 175 (53%) 201 (61%)
z 22.18 24.52 2.50 1.62
P 0.015 0.000 0.006 0.052
90% CI (–2.1%,8.3%) (–6.0%,2.5%) (–7.0%,4.3%) (–10.1%,1.1%)
TRM indicates treatment-related mortality; CI, confidence interval; LFS, leukemia-free survival; OS, overall survival.
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32% (2%) and 31% (3%) for the BM and PBSC
arms, yielding a 90% confidence interval for the differ-
ence of (–5%, 7%). This interval is entirely above
–10%, indicating that BM is no more than 10% worse
than PBSC in terms of 3-year LFS. Note that this com-
parison does not adjust for risk factors; we illustrate
such techniques in the next example.
Example 2: Choice of a 7/8 Unrelated Donor
In this example we consider the choice of a 7/8 al-
lele matched unrelated donor for use in a transplant for
leukemia. The data is from the study by Lee et al. [1] of
unrelated donors who received cells from BM. In the
study there were 274 cases where the donor was mis-
matched at the A loci only, 116 at B only, 478 at C
only, and 117 mismatched at DRB1 only. Of interest
is testing the equivalence of the 4 donor types in terms
of 1-year survival. For illustration we will perform
6 pairwise equivalence tests with no adjustment for
multiple testing.
We first look at unadjusted tests. Here we will per-
form the tests using a d of 0.10 and a 5% type I error.
We see in Table 4 using this rather liberal definition of
equivalence that the survival of the A and C, and that of
the B and C locus mismatched patients is equivalent
because the corresponding 90% confidence intervals
are contained in the interval (–0.1, .1). However, we
cannot conclude that the A and B locus mismatched
patients are equivalent, and there is no evidence of
equivalence between any of the Class I mismatches
and the DRB1 mismatch.
We next look at the equivalence test adjusted for
some covariates that influence survival. We will adjust
the comparison for recipient age (0-9 n 5 188; 10-19
n 5 152, 20-29 n 5 174, 30-39 n 5 222, 40-49Table 4. Unadjusted Equivalence Testing for 7/8 Matched
Unrelated Donor Transplants Donor
90% CI for Difference with
Location
of Mismatch S(1) SE of S(1) A B C
A 0.4088 0.0297
B 0.4397 0.0461 (–0.06, 0.12)
C 0.4448 0.0228 (–0.03, 0.10) (–0.08,0.09)
DRB1 0.3846 0.045 (–0.11, 0.06) (–0.16,0.05) (-0.14,0.02)n5 229,$50 n5 88), Disease stage at transplant (early
n 5 378, intermediate n 5 410, and advanced n 5 195)
and recipient race (White n 5 857, Black (50),
Hispanic (52), or other (24)). We will fit a relative
mortality model for 1-year survival based on the
pseudo-observation approach and a complimentary
log-log link. The model, when examining equivalence
of A mismatched transplants to the other types of
transplants includes a set of binary covariates describ-
ing HLA matching like XB 5 {1 if donor was B mis-
matched only, 0 otherwise}, XC, XDRB1, and the usual
covariates for age, race, and disease status. We will de-
fine equivalence in terms of a relative risk of the 1-year
mortality being between 0.75 and 1.33 and test this hy-
pothesis at a 5% level using a 90% confidence interval
as discussed above. Here the value of .75 corresponds
to about a 10% difference in 1-year survival between
the donor groups when the true survival in the A group
is 50%. Based on the data and the fitted model the ac-
tual maximal difference between the 1-year survival in
the A arm(Treatment) as compared to the other donor
choices is, for example, 0.092 for a 0-9-year-old White
patient with early disease: A mismatched survival esti-
mated at SA(1) 5 0.69, 0.105 for a 30-39-yea- old
White patient with early disease, SA(1) 5 0.49, or
0.101 for a 40-49-year-old patient with advanced dis-
ease, SA(1) 5 0.21.
Table 5 shows the 90% confidence intervals for the
relative risk of death at 1 year. Here we can conclude
that C and B mismatches have equivalent 1-year sur-
vival.CONCLUSION
We have shown that tests for the equivalence or
noninferiority of treatments are possible in HSCT
studies. In many cases these may be of greater interestTable 5. Tests for Equivalence of 1-Year Survival by Donor
Type Adjusted for Patient Age, Race, and Disease Status
‘‘Control’’ ‘‘Treatment’’ 90% Confidence Interval
A Mismatched B Mismatched (0.66,1.11)
C Mismatched (0.71,1.02)
DRB1 Mismatched (0.81,1.36)
B Mismatched C Mismatched (0.79,1.27)
DRB1 Mismatched (0.91,1.67)
C Mismatched DRB1 Mismatched (0.97,1.57)
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is a difference. They may be particularly useful in de-
ciding on alternative donors, sources of stem cells or
other transplant therapies.
The simplest approach to noninferiority or equiv-
alence is based on a modified confidence interval ap-
proach. These confidence intervals can be based on
any meaningful parameter comparing the treatment
and control group. Although the tests are simple in
concept they are complicated by the need for larger
than usual sample sizes. An additional major difficulty
in applying these techniques is in defining for the pa-
rameter meaningful clinical bounds on what it means
to be noninferior.ACKNOWLEDGMENTS
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